Turnstone Biologics Reports Encouraging Phase 1 Results
Company Announcements

Turnstone Biologics Reports Encouraging Phase 1 Results

Turnstone Biologics Corp. (TSBX) just unveiled an update.

Turnstone Biologics Corp. has shared promising initial data from its Phase 1 clinical trials for TIDAL-01, sparking investor interest. The details were released in a recent press statement and further elaborated in an updated corporate presentation on their website. This information, while informative, is not considered part of the formal financial filings but is accessible for those tracking the company’s progress.

For detailed information about TSBX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyTurnstone Biologics downgraded to Neutral at BofA after restructuring
TheFlyTurnstone Biologics downgraded to Neutral from Buy at BofA
TipRanks Auto-Generated NewsdeskTurnstone Biologics Streamlines Operations and Leadership
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App